Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.65 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25703791 | 0.92 | KDM4C (0.57) | MAPTKDM4CALDH1A1LMNANPSR1 | |
| SCHEMBL27030232 | 0.87 | KDM4C (0.57) | MAPTKDM4CALDH1A1LMNANPSR1 | |
| SCHEMBL15270392 | 0.85 | GAA (0.56) | MAPTALDH1A1LMNAHPGDNPSR1 | |
| SCHEMBL31252847 | 0.85 | GAA (0.56) | MAPTALDH1A1LMNAHPGDNPSR1 | |
| SCHEMBL28124742 | 0.83 | KDM4C (0.67) | MAPTKDM4CALDH1A1LMNAHPGD | |
| SCHEMBL23042991 | 0.82 | MAPT (0.63) | MAPTKDM4CALDH1A1LMNAHPGD | |
| SCHEMBL5888233 | 0.80 | PDE5A (0.60) | MAPTNPSR1GAAKMT2APOLB | |
| SCHEMBL22303187 | 0.80 | MAPT (0.65) | MAPTKDM4CALDH1A1LMNAHPGD | |
| SCHEMBL22892765 | 0.78 | NR3C1 (0.51) | MAPTKDM4CKMT2A | |
| SCHEMBL12992231 | 0.78 | MAPT (0.65) | MAPTKDM4CALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMAC, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| CN-113330014-B | Polycyclic compounds that inhibit MNK1 and MNK2 | 诺沃斯达药业(上海)有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023098832-A1 | PYRIDOPYRIMIDINE DERIVATIVES SERVING AS SMALL GTP ENZYME KRAS MUTATION INHIBITORS | 思路迪生物医药(上海)有限公司 | 2023-06-08 | — | — | WO | disclosed |
| CN-111484494-B | Polycyclic compounds that inhibit MNK1 and MNK2 | 诺沃斯达药业(上海)有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | disclosed |
| CN-113330014-A | Polycyclic compounds that inhibit MNK1 and MNK2 | 诺沃斯达药业(上海)有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| CN-111484494-A | Polycyclic compounds that inhibit MNK1 and MNK2 | 诺沃斯达药业有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9567334-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-3102577-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | Principia Biopharma Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9493454-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493454-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-07-14 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
| WO-2015120049-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | MAPT 2809/4885KDM4C 3500/4885ALDH1A1 4398/4885 |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | MAPT 2809/4885KDM4C 3500/4885ALDH1A1 4398/4885 |
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | MAPT 3654/4885KDM4C 4090/4885ALDH1A1 2943/4885 |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | MAPT 3613/4885KDM4C 3273/4885ALDH1A1 1116/4885 |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | MAPT 3613/4885KDM4C 3273/4885ALDH1A1 1116/4885 |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAPT 3613/4885KDM4C 3273/4885ALDH1A1 1116/4885 |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | FGFR1, FGFR3, FGFR2 | MAPT 3239/4885KDM4C 2433/4885ALDH1A1 938/4885 |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | FGFR1, FGFR3, FGFR2 | MAPT 3613/4885KDM4C 3273/4885ALDH1A1 1116/4885 |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAPT 3613/4885KDM4C 3273/4885ALDH1A1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.